2022 - Optimizing Preclinical Drug Development through Immune Receptor Sequencing in Mouse Models
Date2022-11-10
Deadline2022-11-10
VenueWebinar, USA - United States
KeywordsDrug Development; Preclinical; Preclinical Development
Topics/Call fo Papers
In this webinar, learn about optimizing preclinical drug development by decoding the vast genetic information stored in a patient’s immune receptors – T cells and B cells – and utilizing this data toward the development of targeted therapies.
Adaptive Biotechnologies’ unique Immune Medicine Platform is capable of profiling immune receptors at high throughput, enabling drug development in both in vitro and mouse models of disease. This data-driven system can reveal which diseases a patient’s immune system has been fighting and identify and characterize which T-cell receptors may be most effective for cellular therapies or which B-cell receptors produce the most effective antibodies to fight or neutralize disease.
The featured speaker will cover the principles of the immunosequencing platform including the basics of T-cell and B-cell receptor structure, VDJ recombination and concepts governing immune receptor diversity. In addition, Adaptive’s multiplex PCR and amplification bias-controlled approach to quantitatively assessing T cells and B cells and applications including clone tracking, monitoring repertoire diversity and clonality, measuring clonal expansion and contraction and calculating lymphocyte infiltration will be discussed.
The speaker will talk about identifying candidate drugs, performing PK/PD studies, establishing preclinical dosing, determining initial dose-scheduling, and identifying new biomarkers in a variety of disease setting including, but not limited to, solid tumors, hematopoietic malignancies, autoimmune diseases, and infectious diseases. The webinar will also explore various treatment modalities including immunotherapies and checkpoint inhibitors, immunosuppressive drugs, transplantation, and vaccine development.
Register for this webinar to learn how immunosequencing in preclinical mouse models can accelerate preclinical drug development and discovery.
Research Use Only. Not for use in diagnostic procedures
Adaptive Biotechnologies’ unique Immune Medicine Platform is capable of profiling immune receptors at high throughput, enabling drug development in both in vitro and mouse models of disease. This data-driven system can reveal which diseases a patient’s immune system has been fighting and identify and characterize which T-cell receptors may be most effective for cellular therapies or which B-cell receptors produce the most effective antibodies to fight or neutralize disease.
The featured speaker will cover the principles of the immunosequencing platform including the basics of T-cell and B-cell receptor structure, VDJ recombination and concepts governing immune receptor diversity. In addition, Adaptive’s multiplex PCR and amplification bias-controlled approach to quantitatively assessing T cells and B cells and applications including clone tracking, monitoring repertoire diversity and clonality, measuring clonal expansion and contraction and calculating lymphocyte infiltration will be discussed.
The speaker will talk about identifying candidate drugs, performing PK/PD studies, establishing preclinical dosing, determining initial dose-scheduling, and identifying new biomarkers in a variety of disease setting including, but not limited to, solid tumors, hematopoietic malignancies, autoimmune diseases, and infectious diseases. The webinar will also explore various treatment modalities including immunotherapies and checkpoint inhibitors, immunosuppressive drugs, transplantation, and vaccine development.
Register for this webinar to learn how immunosequencing in preclinical mouse models can accelerate preclinical drug development and discovery.
Research Use Only. Not for use in diagnostic procedures
Other CFPs
- Deploying a Patient-First Framework to Accelerate Recruitment & Reduce Overall Trial Timelines
- Driving Outcomes in Medical Affairs — Leveraging Technology to Identify Successful MSL-KOL Relationships
- Detection of COVID-19 Viral RNA in Wastewater as a Simple and Sensitive Method of Outbreak Detection in Large Populations
- The Need for Standardization and CDISC: Insights from The University of Alabama, The University of Utah & CDISC
- How can Humanized Mouse Models be Used to Study Cancer & the Development of New Immune-Targeted Therapies?
Last modified: 2022-11-02 02:04:31